Ritter Pharmaceuticals develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. They are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient’s health.
